Non-nucleoside inhibitors of the HCV NS5B polymerase: progress in the discovery and development of novel agents for the treatment of HCV infections.

Non-nucleoside inhibitors of the HCV NS5B polymerase: progress in the discovery and development of novel agents for the treatment of HCV infections. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Non-nucleoside inhibitors of the HCV NS5B polymerase: progress in the discovery and development of novel agents for the treatment of HCV infections. Abstract Text:

Pierre L Beaulieu,

The severe health conditions associated with chronic HCV infection remain a global concern. Small-molecule drugs that specifically target essential virally encoded enzymes have not yet progressed to market, and the current standard of care continues to rely on a combination of pegylated IFN with ribavirin. This therapy has serious side effects and a significant proportion of patients infected with HCV genotype 1 (the major genotype in industrialized countries) have an unsatisfactory outcome with this therapy. Major advances have been realized in the development of specific non-nucleoside inhibitors of the viral NS5B RNA-dependent RNA polymerase. This well-characterized replicative enzyme is a highly drugable target that, in addition to its active site, features at least three known allosteric binding pockets that regulate RNA synthesis and are suitable for inhibitor design. Clinical proof-of-concept for allosteric non-nucleoside HCV polymerase inhibitors has been reported and several compounds have progressed into preclinical studies. It is likely that in the future NS5B inhibitors will form an integral part of more effective anti-HCV therapies, combining the use of small-molecule antiviral drugs with or without the assistance of immune modulators such as IFNs in order to minimize the emergence of resistance.

Non-nucleoside inhibitors of the HCV NS5B polymerase: progress in the discovery and development of novel agents for the treatment of HCV infections. Publishing Authors By Initials

PL Beaulieu,

For similar biological phenomena, cell phenomena, and immunity: biological phenomena: microbiologic phenomena: viral physiology: virus replication research abstracts see: biological phenomena, cell phenomena, and immunity: biological phenomena: microbiologic phenomena: viral physiology: virus replication research

PUBMED ID PMID:

MEDLINE DATE:

Non-nucleoside inhibitors of the HCV NS5B polymerase: progress in the discovery and development of novel agents for the treatment of HCV infections. Journal Published:

PUBLICATION TYPE: Review

Journal: Current opinion in investigational drugs (London,

VOLUME: 8

Page Numbers: 614-34

Journal Abbreviation:

ISSN: 1472-4472

DAY: 27

MONTH: Aug

YEAR: 2007

Non-nucleoside inhibitors of the HCV NS5B polymerase: progress in the discovery and development of novel agents for the treatment of HCV infections. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 100965718

Non-nucleoside inhibitors of the HCV NS5B polymerase: progress in the discovery and development of novel agents for the treatment of HCV infections. Keywords Mesh Terms:

KEYWORDS: Virus Replication

MESH TERMS: drug effects

Chemical & Substance for Abstract: Non-nucleoside inhibitors of the HCV NS5B polymerase: progress in the discovery and development of novel agents for the treatment of HCV infections. Information

Substance Name: RNA Replicase

Registry Number: EC 2.7.7.48

Grant and Affiliation Information for Non-nucleoside inhibitors of the HCV NS5B polymerase: progress in the discovery and development of novel agents for the treatment of HCV infections.

AFFILIATION: Boehringer Ingelheim (Canada) Ltd, Research and Development, 2100 Cunard Street, Laval, Québec H7S 2G5, Canada. pbeaulieu@lav.boehringer-ingelheim.com

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Curr Opin Investig Drugs

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Non-nucleoside inhibitors of the HCV NS5B polymerase: progress in the discovery and development of novel agents for the treatment of HCV infections Related Publications

• Abduction and external rotation in shoulder impingement: an open MR study on healthy volunteers initial experience.
• Asymmetric closure of ischiopubic synchondrosis in pediatric patients: correlation with foot dominance.
• Balanced SSFP imaging of the musculoskeletal system.
• Correction of megavoltage cone-beam CT images for dose calculation in the head and neck region.
• Depth-resolved chromophore analysis of bovine retina and pigment epithelium by photoacoustic spectroscopy.
• Differential expression of claudin-2 along the human intestine: Implication of GATA-4 in the maintenance of claudin-2 in differentiating cells.
• Diffusion tensor tractography of the limbic system.
• Effect of UV irradiation on cut cantaloupe: terpenoids and esters.
• Evolution theory: an overview of its applications in psychiatry.
• Genome size scaling through phenotype space.
• Light exposure in the natural environment: relevance to mood and sleep disorders.
• Messing up with traffic: different effects of antipsychotic agents on glutamate receptor complexes in vivo.
• Microstructural maturation of the human brain from childhood to adulthood.
• Musculoskeletal MRI at 3.0 T: initial clinical experience.
• Musculoskeletal MRI at 3.0 T: relaxation times and image contrast.
• Non-nucleoside inhibitors of the HCV NS5B polymerase: progress in the discovery and development of novel agents for the treatment of HCV infections.
• Pharmacological management of atypical antipsychotic-induced weight gain.
• Recent advances in the pharmacological management of pain.
• Sodium imaging optimization under specific absorption rate constraint.
• Synergistic antinociceptive effects of anandamide, an endocannabinoid, and nonsteroidal anti-inflammatory drugs in peripheral tissue: a role for endogenous fatty-acid ethanolamides?
• Tako-tsubo cardiomyopathy.
• The local antinociceptive effects of paracetamol in neuropathic pain are mediated by cannabinoid receptors.
• The neurobiology of treatment response to antidepressants and mood stabilizing medications.
• Transparent rendering of intraluminal contrast for 3D polyp visualization at CT colonography.
• Using biphasic CT to reveal gastrointestinal arteriovenous malformations.
• Volume rendering of CT data: applications to the genitourinary tract.
• Volume rendering of tendon-bone relationships using unenhanced CT.
• [Influence of cortisone on the different urinary steroids of patients with congenital hyperplasia of the adrenal cortex.]
• [New light on chronic hypokalemia with urinary corticoid excess; proof of hyperaldosteronuria.]
• [To change death one would have to change life.]